Dec 22, 2020 7:00am EST Tonix Pharmaceuticals Acquires Exclusive License to University of Geneva Technology for Oxytocin-Based Treatments for Treating Insulin Resistance, Diabetes and Obesity, Expanding Proprietary Uses for TNX-1900 (Intranasal Potentiated Oxytocin)
Dec 21, 2020 7:00am EST Tonix Pharmaceuticals Reports Topline Results from Phase 3 RECOVERY Study of TNX-102 SL in PTSD and Outlines Future Development Plans
Dec 7, 2020 7:00am EST Tonix Pharmaceuticals Announces Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia
Dec 4, 2020 8:00am EST Vaccine Genome Researchers Report 99.7% Colinear Identity Between a U.S. Civil War Era Smallpox Vaccine and Horsepox Virus
Nov 16, 2020 7:00am EST Tonix Pharmaceuticals Reports Positive Immune Response Results from COVID-19 Vaccine Candidate TNX-1800, Following Vaccination of Non-Human Primates
Nov 12, 2020 4:31pm EST Tonix Pharmaceuticals Outlines New Statistical Method to Analyze Future PTSD Studies at the 3rd Annual Neuropsychiatric Drug Development Summit
Nov 9, 2020 4:15pm EST Tonix Pharmaceuticals to Present at 3rd Annual Neuropsychiatric Drug Development Summit
Nov 9, 2020 8:30am EST Tonix Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights
Oct 15, 2020 7:00am EDT Tonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Facilitate Development of Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics
